Abstract: The present disclosure includes embodiments for restricting or varying digital access or digital functionality based on health data. In one example, a method to vary functionality for an application is disclosed. The method includes receiving health data corresponding to a health status of a user, determining that the health status does not satisfy a health standard for an organization, and disabling at least one function for an application communicating with one or more devices of the organization based on the health status.

Abstract: The present disclosure includes embodiments for restricting or varying digital access or digital functionality based on health data. In one example, a method to vary functionality for an application is disclosed. The method includes receiving health data corresponding to a health status of a user, determining that the health status does not satisfy a health standard for an organization, and disabling at least one function for an application communicating with one or more devices of the organization based on the health status.

Abstract: The disclosure directed to methods for measuring an analyte alone or in combination with total protein in biological samples. More particularly, the disclosure relates to methods for measuring an analyte and/or total protein using one or more colorimetric reagents alone or in combination with protein precipitation reagents.

Abstract: The present disclosure relates to systems and methods of control access to a controlled-access area. In one embodiment the method includes analyzing health data corresponding to a user to determine that the health data satisfies a health standard for an organization controlling the access-controlled location and the health data was captured at a sensing location offsite from the access-controlled location. In one embodiment the method includes determining that the user has authorization from the organization to enter the access-controlled location; and authorizing the user to enter the access-controlled location.

Abstract: The present disclosure relates to systems and methods of control access to a controlled-access area. The method includes receiving offsite sensor data, receiving offsite user identification data corresponding to the offsite sensor data, determining that the offsite sensor data satisfies an organizational standard, determining that the offsite user identification data corresponds to an approved user, and transmitting a notification to a user device. The method may also include receiving onsite user information and using the offsite sensor data and the onsite user information to determine if a user is approved for access to an access-controlled area. In some examples, the offsite sensor data may be temperature data associated with a febrile condition of a user attempting to gain access to the controlled-access area.

Abstract: Described herein is a temperature device, including systems and methods associated therewith. The temperature device may include a housing. The temperature device may further include an actuation feature associated with the housing and configured to receive a user input. The temperature device may further include a sensing feature recessed within the housing and configured to detect a temperature condition in response to a receipt of the user input. The temperature device may further include a communication module operatively connected to the sensing feature and configured to transmit and receive information associated with a detection of the temperature condition.

Abstract: The present invention provides a simple and efficient cipher and key generation and selection capability from a predetermined, randomly changing, fixed size matrix (N) of ciphers and keys resulting in a very high-order approximation (Nr,c??) of a true One Time Pad for encryption solutions such as the CipherLoc Polymorphic Key Progression Algorithmic Cipher Engine. The ciphers are randomly selected from a pool of user supplied ciphers, FIPS 140-2 or other certified ciphers and the keys are produced from various methods for generating a key that includes reading a data stream from a network or a Cryptographic Pseudo Random Number Generator (CPRNG)/Pseudo Random Number Generator (PRNG) or a Predetermined Cryptographic Key Generator (PCKG) or any combination of all. Ciphers and generated keys are randomly paired and stored in a volatile matrix for use by an encryption solution.

Abstract: The disclosure directed to methods for measuring an analyte alone or in combination with total protein in biological samples. More particularly, the disclosure relates to methods for measuring an analyte and/or total protein using one or more colorimetric reagents alone or in combination with protein precipitation reagents.

Abstract: The present invention provides a simple and efficient cipher and key generation and selection capability from a predetermined, randomly changing, fixed size matrix (N) of ciphers and keys resulting in a very high-order approximation (Nr,c??) of a true One Time Pad for encryption solutions such as the CipherLoc Polymorphic Key Progression Algorithmic Cipher Engine. The ciphers are randomly selected from a pool of user supplied ciphers, FIPS 140-2 or other certified ciphers and the keys are produced from various methods for generating a key that includes reading a data stream from a network or a Cryptographic Pseudo Random Number Generator (CPRNG)/Pseudo Random Number Generator (PRNG) or a Predetermined Cryptographic Key Generator (PCKG) or any combination of all. Ciphers and generated keys are randomly paired and stored in a volatile matrix for use by an encryption solution.

Abstract: The present invention provides novel isolated and purified polynucleotides and polypeptides related to functional motifs of the Nogo receptor 1 (NgR1) and use of peptides mimicking these functional motifs as antagonists to NgR1 ligands, e.g., myelin-associated glycoprotein, oligodendrocyte myelin glycoprotein, Nogo-A, Nogo-66, an antibody to Nogo receptor, an antibody to GT1b, an antibody to p75 neurotrophin receptor, and an antibody to Lingo-1, etc. The invention also provides antibodies to the mimetic peptide antagonists. The present invention is further directed to novel therapeutics and therapeutic targets and to methods of screening and assessing test compounds for treatments requiring axonal regeneration, i.e., reversal of the effects of NgR1 ligand binding to the NgR1 (i.e., producing inhibition of axonal growth). The present invention also is directed to novel methods for treating disorders arising from inhibition of axonal growth mediated by the binding of NgR1 ligands to the NgR1.

Abstract: The present invention provides novel isolated and purified polynucleotides and polypeptides related to functional motifs of the Nogo receptor 1 (NgR1) (e.g., the binding pocket on the side surface of NgR1, functional motifs comprising the amino acid sequence of FRG, etc.) and use of peptides mimicking these functional motifs as antagonists to NgR1 ligands, e.g., myelin-associated glycoprotein, oligodendrocyte myelin glycoprotein, Nogo-A, Nogo-66, GT1b, an antibody to Nogo receptor, an antibody to GT1b, an antibody to p75 neurotrophin receptor, and an antibody to Lingo-1, etc. The invention also provides antibodies to the mimetic peptide antagonists. The present invention is further directed to novel therapeutics and therapeutic targets and to methods of screening and assessing test compounds for treatments requiring axonal regeneration, i.e., reversal of the effects of NgR1 ligand binding to the NgR1 (i.e., producing inhibition of axonal growth).

Abstract: The present invention relates to novel substrates, to methods of making them and to uses therefor. The substrates of the invention comprise a base portion and a surface layer covering at least part of the base portion, with a binding layer provided therebetween. The surface layer provides, on at least a part of the substrate, topographical features having at least one nano scale dimension. These topographical features are adapted to inhibit cell or tissue growth thereon and/or therebetween.

Abstract: Modulating agents and methods for enhancing or inhibiting cadherin-mediated functions are provided. The modulating agents comprise at least an HAV binding motif, an analogue or peptidomimetic thereof, or an antibody or fragment thereof that specifically binds to such a motif. Modulating agents may additionally comprise one or more cell adhesion recognition sequences recognized by cadherins and/or other adhesion molecules. Such modulating agents may, but need not, be linked to a targeting agent, drug and/or support material.

Abstract: Cyclic peptides and peptidomimetics are provided that bind to and/or modulate activities associated with Trk receptors, including processes associated with the growth and repair of the central nervous system (e.g., neuronal growth and survival, axonal growth, neurite outgrowth and synaptic plasticity). Cyclic peptides and peptidomimetics are also provided that block or reduce the effect of other factors that inhibit growth and/or repair of the central nervous system. Pharmaceutical compositions and other formulations comprising these compounds are provided. In addition, the invention provides methods for using the cyclic peptides and peptidomimetics to modulate Trk mediated activities, including processes such as neuronal growth, survival and recover, axonal growth, neurite outgrowth, and synaptic plasticity. Further, the invention provides methods for promoting central nervous system (CNS) neuron growth by administering a p75 receptor binding agent.

Abstract: Cyclic peptides and peptidomimetics are provided that bind to and/or modulate activities associated with Trk receptors, including processes associated with the growth and repair of the central nervous system (e.g., neuronal growth and survival, axonal growth, neurite outgrowth and synaptic plasticity). Cyclic peptides and peptidomimetics are also provided that block or reduce the effect of other factors that inhibit growth and/or repair of the central nervous system. Pharmaceutical compositions and other formulations comprising these compounds are provided. In addition, the invention provides methods for using the cyclic peptides and peptidomimetics to modulate Trk mediated activities, including processes such as neuronal growth, survival and recover, axonal growth, neurite outgrowth, and synaptic plasticity. Further, the invention provides methods for promoting central nervous system (CNS) neuron growth by administering a p75 receptor binding agent.

Abstract: Modulating agents and methods for enhancing or inhibiting cadherin-mediated functions are provided. The modulating agents comprise at least an HAV binding motif, an analogue or peptidomimetic thereof, or an antibody or fragment thereof that specifically binds to such a motif. Modulating agents may additionally comprise one or more cell adhesion recognition sequences recognized by cadherins and/or other adhesion molecules. Such modulating agents may, but need not, be linked to a targeting agent, drug and/or support material.

Abstract: An apparatus is provided for simulating and monitoring a respiration pattern of a human. The apparatus generally includes a reservoir having an outlet, and actuator disposed in the reservoir for moving fluid in and out of the reservoir, and a control unit coupled to the actuator for controlling the actuator to simulate and monitor a respiration pattern of a human. Also, a method is provided for simulating and monitoring a respiration pattern of a human. The method includes steps of generating a waveform defining the respiration pattern and controlling an actuator to move fluid in and out of a reservoir based on the waveform. The apparatus and method can accurately simulate and monitor a respiration pattern of a human, especially an infant and a young child, and offer a flexibility to stimulate variety of respiration patterns.

Abstract: Modulating agents and methods for enhancing or inhibiting cadherin-mediated functions are provided. The modulating agents comprise at least an HAV binding motif, an analogue or peptidomimetic thereof, or an antibody or fragment thereof that specifically binds to such a motif. Modulating agents may additionally comprise one or more cell adhesion recognition sequences recognized by cadherins and/or other adhesion molecules. Such modulating agents may, but need not, be linked to a targeting agent, drug and/or support material.

Abstract: Modulating agents and methods for enhancing or inhibiting cadherin-mediated functions are provided. The modulating agents comprise at least an HAV binding motif, an analogue or peptidomimetic thereof, or an antibody or fragment thereof that specifically binds to such a motif. Modulating agents may additionally comprise one or more cell adhesion recognition sequences recognized by cadherins and/or other adhesion molecules. Such modulating agents may, but need not, be linked to a targeting agent, drug and/or support material.